1/2014
vol. 39
Effects of microRNA-21 on the interleukin 12/signal transducer and activator of transcription 4 signaling pathway in asthmatic mice
(Centr Eur J Immunol 2014; 39 (1): 40-45)
Online publish date: 2014/04/17
Get citation
PlumX metrics:
Introduction
Bronchial asthma is a common disease of the respiratory system [1]. The main clinical symptoms of this disease include episodic wheezing, shortness of breath, chest tightness, and coughing. A small number of patients complain of chest pain and present with other clinical manifestations following contact with irritating substances or allergens [2, 3]. It has been shown that the interleukin 12 (IL-12)/signal transducer and transcription activator 4 (STAT4) signal transduction pathway is involved in the development of asthma [4-6]. Expression of IL-12 can be regulated by microRNA-21 (miRNA-21) in IL-4 transgenic mice [7-9]; however, it is not known whether miRNA-21 influences the IL-12/STAT4 signaling pathway in asthmatic mice.
In this paper, we used an established asthmatic mouse model to investigate the effects of miRNA-21 on the regulation of the IL-12/STAT4 pathway during allergic asthma. We observed pathological changes in lung tissue morphology, counted the total cells and EOS cells in BALF, and detected the expression of miRNA-21. We also investigated the expression levels of IL-12 and STAT4 in lung tissue of an asthmatic mouse model. Our aims were to study the effect of miRNA-21 regulation on the IL-12/STAT4 pathway in lung tissue of asthmatic mice and the possible effects of miRNA-21 expression levels on the occurrence and development of asthma.
Material and methods
Mice
We purchased 45 specific pathogen-free (SPF) male mice with a C57BL/6 background (20-22 g) from Shanghai SLAC Laboratory Animal Co., Ltd. (China). The mice used in the studies were sacrificed when they were 6-8-weeks-old.
Laboratory equipment
Real-time polymerase chain reaction (qPCR) thermal cycler (Agilent-Stratagene, USA); electrophoresis apparatus (BioRad, USA); western blot transfer unit (BioRad, USA); electric atomizer (GSK, UK); microplate reader (AI, USA); optical microscope (Olympus, Japan).
Establishment of asthmatic mouse model
Mice were housed under SPF conditions at 24 ±2°C and 55 ±5% relative humidity with a 12-h light-dark cycle. A commercial diet and potable water were available ad libitum. All experiments were approved by the Animal Research Ethics Board of Lishui University (Lishui, Zhejiang Province, China). Mice were randomly divided into three groups (n = 15 mice per group): the model group; the dexamethasone treatment group; and the control group. On days 0 and 8, mice were administered ovalbumin (OVA; Sigma, USA) dissolved in 1.0 ml of aluminum hydroxide gel (60 µg of OVA and 2.25 mg of aluminum hydroxide gel) by intraperitoneal (i.p.) injection. Commencing on day 15, mice in the model group received an ultrasonic nebulization of 2% OVA in a 5 ml solution for 30 min every other day over 7 days. Mice in the dexamethasone treatment group received an i.p. injection of 0.3 mg/kg dexamethasone (Sigma, USA) prior to OVA nebulization. Mice in the control group received saline instead of OVA.
Hematoxylin/eosin (HE) staining of lung tissue
A portion of the right upper lung tissue was obtained, fixed with 4% paraformaldehyde, dehydrated and embedded in paraffin, then sectioned (5-µm thickness). Sections were baked for 1 h at 60°C, hydrated through a graded ethanol series, and stained for 10 min with hematoxylin, then stained for 3 min with eosin. After washing under running tap water, sections were dehydrated through a graded alcohol series, treated with xylene, and mounted with neutral gum. Pathological changes in sections were observed using an optical microscope.
Cell count within bronchoalveolar lavage fluid (BALF)
Mice in all groups were anaesthetized through an i.p. injection of 5 ml/kg 20% urethane solution after the last OVA nebulization event. Serum and left lung tissue was collected from each mouse; bronchoalveolar lavage was conducted and BALF collected. The total cell number and number of eosinophils (EOS) were counted using a microscope and a high power field-of-view.
Real-time polymerase chain reaction analysis of microRNA-21 expression in lung tissue
A portion of the right lung from each mouse was obtained, and total RNA extracted using Trizol (Invitrogen, USA). We used electrophoresis to determine the quality of the extracted RNA by observing bands corresponding to 28S, 18S and 5S RNA. The purity and quantity of RNA samples was determined by measuring the absorbance at 260 (A260) and 280 nm (A280) and calculating the A260/280 ratio. Only samples with an A260/280 ratio greater than 1.8 were used. We used 1 µg of total RNA for reverse transcription reactions. The generated cDNA (1 ml) was used as a template in qPCR assays which comprised 25 ml. A melt curve for each amplicon was created to determine the specificity of the amplification reaction. We used U6 SnRNA as an internal control.
Western blotting analysis of interleukin 12 and signal transducer and activator of transcription 4 in lung tissue
Proteins were extracted from the lower right section of lung tissues following homogenization of the tissue and the application of a lysis buffer. The concentration of proteins in each sample was determined, and then samples were subjected to polyacrylamide gel electrophoresis (PAGE) for 2 h at 100 V. Proteins were transferred to membranes (0.5 A, 60 min) and probed with goat anti-mouse IL-12 (1 : 100 dilution; Santa Cruz Biotechnology, USA) and goat anti-mouse STAT4 (1 : 100; Santa Cruz Biotechnology, USA) antibodies at 4°C overnight. Samples were repeatedly washed with phosphate-buffered saline (PBS) for 5 min, then incubated with a horseradish peroxidase (HrP)-conjugated rabbit anti-goat antibody (1 : 4000; Sigma, USA) at room temperature for 1 h. Positive signals were detected using chemiluminescence techniques. We used -tubulin as an internal control.
Immunohistochemical analysis of interleukin 12 and signal transducer and activator of transcription 4 in lung tissues
Formalin-fixed paraffin-embedded lung tissue sections were de-waxed, then rehydrated through a graded alcohol series. Sections were treated with 3% (v/v) H2O2 to inhibit endogenous peroxidase activity. The antigen was retrieved by microwaving, and sections blocked using normal sheep serum. Sections were then probed with IL-12- and STAT4-specific primary (1 : 100; Santa Cruz Biotechnology, USA) and secondary (1 : 4000; Sigma, USA) antibodies. We added SP (Jiangsu Beyotime, China) reagent and 3,3’-diaminobenzidine (DAB; Beyotime, Jiangsu, China) to visualize positive brown signals. Nuclear staining was conducted using hematoxylin. Sections were dehydrated and mounted with gum, then examined using a microscope. Differences in protein expression levels among different groups were compared by calculating the average gray value.
Statistical analysis
Data were analyzed using SPSS18.8 (SPSS Inc., USA). The values we have presented are the mean ± standard deviation (X ± s). Single factor analysis of variance (ANOVA) was used for data comparison among groups. A Bonferroni test was used to determine homogeneity of variance, and Dunnett’s T3 analysis was used when variance was missing. A P-value of less than 0.05 was considered statistically significant.
Results
Pathological changes in lung tissues
Alveolar wall tissues of mice in the control group had an integral structure. The alveolar cavity exhibited no exudation, and the alveolar wall had not thickened (Fig. 1A). The alveolar wall structure in the model group was damaged, with the alveolar wall thickened, and a large number of inflammatory cells had infiltrated around the bronchus (Fig. 1B). Lung tissue alveolar wall damage and inflammatory cell infiltration in the dexamethasone group were decreased compared with that in the model group (Fig. 1C).
Bronchoalveolar lavage fluid results
The number of cells in BALF samples from the control, model, and dexamethasone groups is presented in Table 1. The total cell and EOS numbers in BALF samples in the model group were significantly higher than those in mice of the control group. These values were significantly reduced (p < 0.05) following dexamethasone intervention, but still higher than those in normal mice.
Expression profile of microRNA-21 in lung tissues
Expression levels of miRNA-21 mRNA in the control, model, and dexamethasone groups are presented in Table 2. The miRNA-21 expression levels in asthmatic mice from the model group were significantly higher (p < 0.05) than those in normal mice from the control group. Expression levels of miRNA-21 were significantly lower (p < 0.05) in mice treated with dexamethasone, but still higher than those in normal mice.
Expression of interleukin 12 and signal transducer and activator of transcription 4 in lung tissues
Lung IL-12 and STAT4 protein expression levels are presented in Fig. 2, and integral optical density ratios compared in Table 3. Interleukin 12 and STAT4 levels in asthmatic mice of the model group were significantly reduced (p < 0.05) compared with control mice. Interleukin 12 and STAT4 protein expression levels were significantly improved (p < 0.05) following glucocorticoid intervention; however, these levels were still lower than those in control mice.
Immunohistochemical detection of interleukin 12 and signal transducer and activator of transcription 4 in lung tissues
The expression of IL-12 and STAT4 in the lung tissues of asthmatic mice from the model group were significantly decreased (p < 0.05) compared with those in the control group. Expression levels were significantly enhanced (p < 0.05) following dexamethasone intervention. Interleukin 12 was expressed in the cytoplasm, and STAT4 was expressed mainly in the nucleus with some expression seen in the cytoplasm (Figs. 3 and 4).
Discussion
Research has shown that a variety of miRNAs can affect the occurrence and development of asthma [10, 11]. Wang et al. [12] showed that miRNAs can lead to degradation of mRNA and inhibit protein translation. These miRNAs bind to corresponding target sites on the 3’-untranslated region (UTR) of the mRNA, thereby achieving post-translational regulation of gene transcription. Changes in the expression levels of miRNA133a [13], miRNA26a [14] and miRNA155 [15, 16] can lead to changes in the airway, such as remodeling, thereby aggravating asthma symptoms.
In asthmatic mice, the alveolar wall is damaged by increased secretions. The number of inflammatory cells around the airway is significantly increased. However, injuries are improved after dexamethasone intervention. The total cell number, along with the number of EOS in BALF samples in asthmatic mice are significantly higher (p < 0.05) than those in normal mice; however, these numbers are significantly decreased (p < 0.05) following dexamethasone intervention, but still higher than those in normal mice. We found that miRNA-21 expression levels were significantly higher (p < 0.05) in asthmatic mice compared with those in normal mice. These miRNA levels were significantly decreased (p < 0.05) following glucocorticoid intervention, but still higher than those seen in control mice. Western blotting and immunohistochemistry results showed that IL-12 and STAT4 protein levels in the lungs of asthmatic mice were significantly reduced
(p < 0.05) compared with those in control mice. Interleukin 12 and STAT4 protein levels were significantly improved (p < 0.05) after glucocorticoid intervention, but were still lower than those in control mice.
Recent studies have shown that miRNA-21 target sites are located within IL-12 mRNA, therefore miRNA-21 can significantly inhibit the translation process after IL-12 transcription [17]. Our findings indicate that miRNA-21 can regulate IL-12 and STAT4 translation post-transcriptionally, resulting in less IL-12 and STAT4 proteins. Our results reflect those of previous studies. Interleukin 12 is an important cell factor in maintaining the Th1/Th2 balance in the body [18-20]. The receptors are dimerized by combining with IL-12 receptors at the T0 cell surface, with JAK kinases activated by the dimerized receptor. This triggers phosphorylation of intracellular receptors that area tyrosine residues. Phosphorylated intracellular receptors begin to raise STAT4 levels and transfer it to the nucleus, where STAT4 is combined with the target gene promoter sequence to promote transcription of the target gene so that T0 cells are differentiated into Th1 cell subsets. The Th1 cell subsets can mediate the cellular immune response and the occurrence of delayed type hypersensitivity reactions. These results indicate that IL-12 can regulate the expression of STAT4, and that IL-12/STAT4 signaling channels can inhibit asthma and other type I allergic reactions [21-24].
We have shown that miRNA-21 expression levels in asthmatic mice are significantly increased, and that miRNA-21 is specific to IL-12 mRNA allowing for inhibition of IL-12 translation. This miRNA also results in reduced STAT4 expression levels, which can lead to Th1/Th2 balance disorders. Type I allergic reactions can occur more easily under the stimulation of external allergens, thereby promoting the occurrence and development of asthma. The expression levels of miRNA-21 are decreased following dexamethasone intervention, such that IL-12 post-transcriptional translation is increased. When IL-12 expression levels are significantly increased, the expression level of STAT4 is increased, thereby promoting re-establishment of the Th1/Th2 balance and reducing the incidence of asthma.
The authors declare no conflict of interest.
This study was supported by Grants of the Zhejiang Provincial Natural Science Foundation of China (No. LY12H10003), the Zhejiang Provincial Medical and Health Foundation of China (No. 2013KYB303), and the Lishui Nonprofit Technology Application Projects of Zhejiang Province of China (No. 2012JYZB29).
References
1. Vissing NH, Jensen SM, Bisgaard H (2012): Validity of information on atopic disease and other illness in young children reported by parents in a prospective birth cohort study. BMC Med Res Methodol 12: 160.
2. Custovic A, Simpson A (2012): The role of inhalant allergens in allergic airways disease. J Investig Allergol Clin Immunol 22: 393-401; quiz follow 401.
3. Lommatzsch M (2012): Airway hyperresponsiveness: new insights into thepathogenesis. Semin Respir Crit Care Med 33: 579-587.
4. Pfitzner E1, Kliem S, Baus D, Litterst CM (2004): The role of STATs in inflammation and inflammatory diseases. Curr Pharm Des 10: 2839-2850.
5. Kim YS, Choi SJ, Choi JP, et al. (2010): IL-12-STAT4-IFN- axis is a key downstream pathway in the development of IL-13-mediated asthma phenotypes in a Th2 type asthma model. Exp Mol Med 42: 533-546.
6. Nathalie S, Jacinta B, Laure B, et al. (2013): IL-12 receptor 1 deficiency alters in vivo T follicular helper cell response in humans. Blood 121: 3375-3385.
7. Munitz A, Brandt EB, Mingler M, et al. (2008): Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha1 and the type II IL-4 receptor in asthma pathogenesis. Proc Natl Acad Sci U SA 105: 7240-7245.
8. Helene MN, Jorg T (2013): Epigenetic changes in inflammatory and autoimmune diseases. Springer Netherlands: Epigenetics: Development and Disease 61: 455-478.
9. Huang Y, Lei Y, Zhang H, et al. (2011): MicroRNA regulation of STAT4 protein expression: rapid and sensitive modulation of IL-12 signaling in human natural killer cells. Blood 118: 6793-6802.
10. Roh SS, Kim SH, Lee YC, Seo YB (2008): Effects of radix adenophorae and cyclosporine A on an OVA-induced murine model of asthma by suppressing to T cells activity, eosinophilia, and bronchial hyperresponsiveness. Mediators Inflamm 2008: 781425.
11. Seguin RM, Ferrari N (2009): Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 18: 1505-1517.
12. Wong CF, Tellam RL (2008): MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis. J Biol Chem 283: 9836-9843.
13. Chiba Y, Tanabe M, Goto K, et al. (2009): Down-regulation of miR-133a contributes to up-regulation of Rhoa in bronchial smooth muscle cells. Am J Respir Crit Care Med 180: 713-719.
14. Hidalgo IJ, Borchardt RT (1990): Transport of bile acids in a human intestinal epithelial cell line, Caco-2. Biochim Biophys Acta 1035: 97-103.
15. O’Connell RM, Taganov KD, Boldin MP, et al. (2007): MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A 104: 1604-1609.
16. Banerjee A, Schambach F, DeJong CS, et al. (2010): Micro-RNA-155 inhibits IFN-gamma signaling in CD4+ T cells. Eur J Immunol 40: 225-231.
17. Lu TX, Munitz A, Rothenberg ME (2009): MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression. J Immunol 182: 4994-5002.
18. Freudenberg MA, Merlin T, Kalis C, et al. (2002): Cutting edge: a murine, IL-12-independent pathway of IFN- induction by Gram-negative bacteria based on STAT4 activation by type I IFN and IL-18 signaling. J Immunol 169: 1665-1668.
19. Zielonka MT, Demkow U, Filewska M, et al. (2007): Angiogenic activity of sera from interstitial lung diseases patients in relation to IL-6, IL-8, IL-12 and TNF serum level. Centr Eur J Immunol 32: 53-60.
20. Rossi A, Cantisani C, Carlesimo M, et al. (2012): Serum concentrations of IL-2, IL-6, IL-12 and TNF-αlpha in patients with alopecia areata. Int J Immunopathol Pharmacol 25: 781-788.
21. Afanasyeva M, Wang Y, Kaya Z, et al. (2001): Interleukin-12 receptor/STAT4 signaling is required for the development of autoimmune myocarditis in mice by an interferon-gamma-independent pathway. Circulation 104: 3145-3151.
22. Lund RJ, Chen Z, Scheinin J, Lahesmaa R (2004): Early target genes of IL-12 and STAT4 signaling in Th cells. J Immunol 172: 6775-6782.
23. Sondergaard JN, Brix S (2012): Isolation of IL-12p70-competent human monocyte-derived dendritic cells. J Immunol Methods 386: 112-116.
24. Cheng X, Folco EJ, Shimizu K, Libby P (2012): Adiponectin induces pro-inflammatory programs in human macrophages and CD4+ T cells. J Biol Chem 287: 36896-36904.
Copyright: © 2014 Polish Society of Experimental and Clinical Immunology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License ( http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
|
|